Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). 

 

The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.

News
Good, Coric named 2017 CURE Entrepreneurs of the Year
12/13/2017
In a ceremony December 12 at the CURE Annual Holiday Party at Alexion in New Haven, the 2017 CURE Entrepreneur of the Year award was presented to Jennifer Good of Trevi Therapeutics and Dr. Vlad Coric of Biohaven Pharmaceuticals, two biotechnology ex...
Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer
10/12/2017
Highly experienced clinical drug developer to oversee R&D functions and Companys Phase 3 development program
Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates
7/20/2017
Company continuing the development of Nalbuphine ER in chronic pruritus conditions